Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654072 | 1.00 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL15478315 | 0.90 | CCR1 (0.46) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL13804506 | 0.90 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL654983 | 0.84 | CCR1 (0.42) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL654984 | 0.84 | CCR1 (0.42) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL7210953 | 0.84 | CCR1 (0.42) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL436923 | 0.82 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2R | |
| SCHEMBL436922 | 0.82 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2R | |
| SCHEMBL7210858 | 0.81 | ALDH1A1 (0.42) | CCR1CHRM2CCR5TBXA2R | |
| SCHEMBL7210855 | 0.81 | ALDH1A1 (0.42) | CCR1CHRM2CCR5TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-1688418-B1 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334283-B2 | CCR1 antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20080139602-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1669356-A1 | CCR1 Antagonists for the treatment of i.a demyelinating inflammatory disease | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1562954-B1 | CCR1 ANTAGONISTS FOR THE TREATMENT OF I.A. DEMYELINATING INFLAMMATORY DISEASE | MILLENNIUM PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1448566-B1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288319-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | CCR1 4/4885CHRM2 821/4885CCR5 6/4885 |
| US-20040106639-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1966/4885CCR5 5/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
| US-20080139602-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
| US-20150005338-A1 | CCR1 ANTAGONISTS AND METHODS OF USE THEREOF | CCR1, CCR3, CCR4 | CCR1 1/4885CHRM2 386/4885CCR5 8/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | CCR1 19/4885CHRM2 615/4885CCR5 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.